Phaseline

Targets › REN

REN (Renin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Genitourinary; next expected readout Dec 2029.

Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of blood pressure and increased sodium retention by the kidney. (UniProt, P00797)

Open in Phaseline: the race on REN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Region SkaneAliskiren
Renin inhibitor
RENPhase 2C3 GlomerulopathyDec 2029

Conditions

C3 Glomerulopathy (1)

Modalities

small molecule (1)

Companies

Region Skane (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.